Interstitial lung disease: Trials and tribulations

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 5, 2008, Pages 427-433

  Afshar, Kamyar ^a,b   Sharma, Om P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diffuse interstitial lung disease; Lung transplantation; Medical therapy; Pulmonary hypertension

Indexed keywords

AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIN; ETANERCEPT; GAMMA1B INTERFERON; ILOPROST; INFLIXIMAB; METHOTREXATE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; RAPAMYCIN; SILDENAFIL;

ADD ON THERAPY; CLINICAL TRIAL; COUGHING; DOWN REGULATION; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SARCOIDOSIS; SCLERODERMA; SMOKING; SURVIVAL; TRANSAMINITIS; UNSPECIFIED SIDE EFFECT; DIFFUSE SCLERODERMA;

HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; PULMONARY FIBROSIS; RISK FACTORS; SARCOIDOSIS, PULMONARY; SCLERODERMA, DIFFUSE;

EID: 53149146343     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283043e58     Document Type: Review

References (48)

1. King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172:268-279.
2. Coultras DB, Hubbard R. Epidemiology of idiopathic pulmonary fibrosis. In: Lynch III JP, editor. Idiopathic pulmonary fibrosis, lung biology in health and disease. New York: Marcel Dekker; 2004. p. 772.
3. Dempsey OJ, Kerr KM, Gomersall L, et al. Idiopathic pulmonary fibrosis: an update. QJM 2006; 99:643-654.
4. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin Proc 2007; 82:939-943.
5. Nagai S, Nagao T, Kitaichi M, et al. Clinical courses of asymptomatic cases with idiopathic pulmonary fibrosis and a histology of usual interstitial pneumonia [abstract]. Eur Respir J 1998; 11:131s.
6. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:285-292.
7. Raghu G, Brown KK, Bradford WZ, et al., Idiopathic Pulmonary Fibrosis Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133.
8. Demedts M, Behr J, Buhl R, et al. High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242.
9. Azuma A, Nukiwa T, Tusobi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.
10. Park JH, Kim DS, Jang SJ, et al. Prognosis of fibrotic interstitial pneumonia: Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-711.
11. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society and the Europena Respiratory Society. Am J Respir Crit Care Med 2000; 161:646-664.
12. American Thoracic Society, European Respiratory Society. ATS/ERS International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:277-304.
13. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159:1061-1069.
14. Buschhausen L, Kamm M, Arns W, et al. Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin. Med Klin (Munich) 2005; 100:161-164.
15. Niden A, Koss M, Boylen CT, Wilcox A. An open label pilot study to determine the potential efficacy of TNFR:Fc (enbrel, etanercept) in the treatment of usual interstitial pneumonitis. Am J Respir Crit Care Med 2002; 165:A728.
16. ParkSH,Saleh D,Giaid A, Michael RP. Increased endothelian-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelian receptor antagonist. Am J Respir Crit Care Med 1997; 156:600-608.
17. King TE, Behr J, Brown K, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81.
18. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007; 28:369-378.
19. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
20. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026-1034.
21. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970.
22. Thomeer MJ, Vanstenkiste J, Verbeken EK, Demedts M. Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respir Med 2004; 98:567-573.
23. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2001; 18:70-74.
24. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127:1064-1071.
25. Rossman MD, Newman LS, Baughman R, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208.
26. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care med 2006; 174:795-802.
27. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006; 55:978-981.
28. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcome of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746-752.
29. Lederer DJ, Chaplain-Shaw CE, O'Shea MK, et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006; 6:398-403.
30. Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269-1274.
31. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131:897-899.
32. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary hypertension. J Am Coll Cardiol 2004; 43:56S-61S.
33. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132:998-1006.
34. Inhaled iloprost in adults with abnormal pulmonary pressure and associated with idiopathic pulmonary fibrosis. Clinical-Trials.gov #NCT00109681. Available at: http://clinicaltrials.gov. [Accessed 5 March 2007]
35. Sitbon O, Humbert M, JaisX, et al. Long-term use of calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111.
36. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35:989-993.
37. Keogh Am, MacDonald P, Williams T, et al. Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH) 6 month quality of life data. J Heart Lung Transplant 2004; 23 (2 Suppl):S54.
38. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of pivotal trials and trial open-label extensions. Ann Rheum Dis 2006; 65:1336-1340.
39. Williams MH, Das C, Handler CE, et al. Systemic scleroderma associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926-932.
40. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257-1263.
41. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004; 63:1009-1014.
42. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Inter Med 2007; 37:485-494.
43. Catapano-Minotti G, Corsonello A, Guadalupi G. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Inter Med 2008; 47:511-513.
44. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128:1483-1489.
45. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 2007; 13:434-438.
46. Milman N, Burton C, Anderson CB, et al. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diff Lung Dis 2005; 22:222-228.
47. TrulockEP, Edwards LB, Taylor DO, et al. Registry of the international society for heart and lung transplantation: twenty-third official adult lung and heartlung transplantation report-2006. J Heart Lung Transplant 2006; 25:880-892.
48. Rufino R, Madi K, Mourad O, et al. Accelerated form of interstitial pulmonary fibrosis in the native lung after single lung transplantation. J Bras Pneumol 2007; 33:733-737.